Literature DB >> 11326485

Scleroderma in association with the use of docetaxel (taxotere) for breast cancer.

G Hassett1, P Harnett, N Manolios.   

Abstract

The taxanes, paclitaxel (Taxol) and docetaxal (Taxotere), are a new class of anti-microtubule agents which have shown cytotoxic activity in a number of solid tumours. Phase I and II trials confirm that docetaxal is highly active in the treatment of metastatic breast cancer. Reported toxicities of docetaxel include, dose limiting neutropenia, alopecia, skin reactions and fluid retention. Here we report the first case of rapid onset, diffuse scleroderma-like illness, which occurred in a 59-year-old female receiving treatment with docetaxel for locally invasive and advanced metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11326485

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

1.  Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report.

Authors:  Murat Özgür Kılıç; Metin Yalaza; Celal İsmail Bilgiç; Cenap Dener
Journal:  J Breast Health       Date:  2015-04-01

Review 2.  Association between systemic sclerosis and breast cancer: eight new cases and review of the literature.

Authors:  David Launay; Rozenn Le Berre; Pierre-Yves Hatron; Jean-Philippe Peyrat; Eric Hachulla; Bernard Devulder; Mohamed Hebbar
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

3.  Risk of cancer in patients with scleroderma: a population based cohort study.

Authors:  C L Hill; A-M Nguyen; D Roder; P Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

4.  Treatment of chronic hepatitis C in a patient affected by systemic sclerosis.

Authors:  Guido Poggi; Laura Villani; Federico Sottotetti; Barbara Tagliaferri; Benedetta Montagna; Alessio Amatu; Giovanni Bernardo
Journal:  Gastroenterol Res Pract       Date:  2009-11-17       Impact factor: 2.260

5.  Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature.

Authors:  George Kyrgias; Kiki Theodorou; Anna Zygogianni; Konstantinos Tsanadis; Stefanos Zervoudis; John Tzitzikas; Michael Koukourakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-01-24

6.  Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study.

Authors:  Tim Y-T Lu; Catherine L Hill; Eliza K Pontifex; Peter J Roberts-Thomson
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

7.  Risk of cancer in patients with scleroderma.

Authors:  J E Pearson; A J Silman
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

8.  Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure.

Authors:  Bumsoo Park; Raghavendra C Vemulapalli; Amit Gupta; Maria E Shreve; Della A Rees
Journal:  Case Reports Immunol       Date:  2017-02-06

Review 9.  Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma.

Authors:  Thanika Ketpueak; Wanitcha Chanloung; Kittiya Na Nan; Chontara Pongsananurak; Nuntana Kasitanon; Worawit Louthrenoo
Journal:  Clin Rheumatol       Date:  2022-09-09       Impact factor: 3.650

10.  Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.

Authors:  Pia Moinzadeh; Carmen Fonseca; Martin Hellmich; Ami A Shah; Cecilia Chighizola; Christopher P Denton; Voon H Ong
Journal:  Arthritis Res Ther       Date:  2014-02-14       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.